-
2024-511957-23-00
5
2025-01-03
Recurrent or Persistent Endometrial Cancer
-
2023-509069-19-00
4
2024-12-12
idiopathic pulmonary fibrosis
-
2024-515870-28-00
5
2024-10-22
Moderate to severe systemic lupus erythematosus
-
2024-511796-15-00
5
2024-10-16
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
-
2023-507851-31-00
5
2024-09-23
Immunoglobulin A Nephropathy (IgAN)
-
2023-506769-67-00
4
2024-09-04
Moderate to Severely Active Ulcerative Colitis
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2024-512747-23-00
5
2024-07-30
Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2023-506457-38-00
5
2024-06-05
Chronic kidney disease (CKD) and hypertension.
-
2023-506906-38-00
5
2024-05-23
Follicular Lymphoma
-
2023-504816-14-00
5
2024-03-08
Endometrial cancer
-
2023-503827-25-01
5
2024-02-16
Non-Small Cell Lung Cancer (NSCLC)
-
2023-503575-21-00
5
2024-01-23
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
-
2022-502102-32-00
5
2023-11-16
Primary Immunoglobulin A (IgA) Nephropathy
-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2023-506821-12-00
5
2023-10-12
Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Me
-
2022-500430-29-00
5
2023-10-11
Myelodysplastic Syndrome (MDS)
-
2022-501346-30-00
5
2023-09-25
Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
-
2024-515047-31-00
5
2023-08-28
Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
-
2022-501419-15-00
5
2023-08-23
Atrial Fibrillation
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2023-507180-19-00
4
2023-04-05
Cancer
-
2023-503444-13-00
5
2023-03-29
Relapsed/refractory multiple myeloma